Pfizer secures six-month Lyrica extension in US

The US Food and Drug Administration (FDA) has granted Pfizer paediatric exclusivity for Lyrica (pregabalin), extending the period of US market exclusivity for the drug by six months.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

UK Supreme Court issues Warner-Lambert v Actavis ruling

14 November 2018 The UK Supreme Court today dismissed Warner-Lambert’s appeal in its pregabalin patent dispute with Actavis, while clarifying the role of plausibility in the sufficiency of patent applications.

Europe

CJEU backs Warner-Lambert in marketing authorisation dispute

18 February 2019 The Court of Justice of the European Union has issued a judgment in favour of Warner-Lambert amid a dispute between the American pharmaceutical company and an administrative body in the Netherlands.

Americas

FDA opens US to Lyrica generics

24 July 2019 The US Food and Drug Administration last week approved nine applications for the first generic versions of Pfizer’s Lyrica.